<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1199">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819415</url>
  </required_header>
  <id_info>
    <org_study_id>HMR-10059</org_study_id>
    <nct_id>NCT01819415</nct_id>
  </id_info>
  <brief_title>Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recherche en Ophtalmologie, Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation Fighting Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Retina Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Insight Instruments</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Synergetics Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to detect the influence of omega-3 supplements on vitreous
      levels of vascular endothelial growth factor (VEGF) in exudative age-related macular
      degeneration (AMD) in patients receiving intravitreal anti-VEGF treatment. Patients are
      randomized to receive either Age-Related Eye Disease Study 1(AREDS-1) supplements formula
      with the addition of Lutein or AREDS-2 supplementation that adds Omega-3 metabolites (DHA
      and EPA) to the formula. Our goal is to take a limited volume of vitreous sample from these
      patients previous to their regular anti-VEGF injection and perform a comprehensive cytokines
      and lipidomic profiling. We hypothesize, based on our previous basic science discovery of a
      potent anti-VEGF action of an Omega-3 metabolite (4-HDHA), that lipid metabolite composition
      and metobolite levels will significantly vary according to VEGF levels. Based on the results
      of this pioneering clinical study, our research team will proceed to evaluate the individual
      anti-angiogenic (vessel growth stopping) properties of the predominant Omega-3 metabolites
      found.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Vitreal VEGF Levels.</measure>
    <time_frame>1 day (At the time of vitreous biopsy)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipidomics Profile</measure>
    <time_frame>1 day (At the time of vitreous biopsy)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Foveal Thickness</measure>
    <time_frame>During at least 12 months of follow-up after vitreous biopsy.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured with spectral-domain optical coherence tomography.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Exudative Age-related Macular Degeneration.</condition>
  <arm_group>
    <arm_group_label>Naive</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-VEGF plus AREDS-1 supplementation.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-VEGF plus AREDS-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Anti-VEGF plus AREDS-2</intervention_name>
    <description>Omega-3 metabolites supplementation</description>
    <arm_group_label>Anti-VEGF plus AREDS-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Anti-VEGF plus AREDS-1</intervention_name>
    <description>Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.</description>
    <arm_group_label>Anti-VEGF plus AREDS-1 supplementation.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  wet AMD eligible for intravitreal anti-VEGF treatment.

          -  Confirmed exudation on SD-OCT.

        Exclusion Criteria:

          -  dry AMD.

          -  Disciform scar.

          -  Smokers.

          -  Morbid obesity.

          -  Patients undergoing other forms of treatment for wet AMD.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio A Rezende, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maisonneuve Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 28, 2013</lastchanged_date>
  <firstreceived_date>March 24, 2013</firstreceived_date>
  <firstreceived_results_date>April 28, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Flavio Rezende</investigator_full_name>
    <investigator_title>Chief of Retina Service, Department of Ophthalmology, University of Montreal</investigator_title>
  </responsible_party>
  <keyword>wet AMD</keyword>
  <keyword>Omega-3</keyword>
  <keyword>VEGF</keyword>
  <keyword>Lipidomics</keyword>
  <keyword>DHA</keyword>
  <keyword>EPA</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment dates: February-August 2011 Location: Maisonneuve-Rosemont Hospital, University of Montreal, Quebec, Canada</recruitment_details>
      <pre_assignment_details>At least 3 months of no other treatments for wet-AMD in groups 1 and 2 and no treatment at all for group 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 3 - Naive</title>
          <description>Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 - Anti-VEGF Plus AREDS-1 Supplementation.</title>
          <description>Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.</description>
        </group>
        <group group_id="P3">
          <title>Group 1 - Anti-VEGF Plus AREDS-2</title>
          <description>Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).</description>
        </group>
        <group group_id="P4">
          <title>Group 4 - Control</title>
          <description>Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 3 - Naive</title>
          <description>Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 - Anti-VEGF Plus AREDS-1 Supplementation.</title>
          <description>Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.</description>
        </group>
        <group group_id="B3">
          <title>Group 1 - Anti-VEGF Plus AREDS-2</title>
          <description>Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).</description>
        </group>
        <group group_id="B4">
          <title>Group 4 - Control</title>
          <description>Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="10"/>
                <measurement group_id="B5" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="10"/>
                <measurement group_id="B5" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Age</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="83.38" spread="2.32"/>
                <measurement group_id="B2" value="79.00" spread="1.98"/>
                <measurement group_id="B3" value="79.6" spread="1.81"/>
                <measurement group_id="B4" value="68.25" spread="3.56"/>
                <measurement group_id="B5" value="77.56" spread="2.42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="8"/>
                <measurement group_id="B5" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="2"/>
                <measurement group_id="B5" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="10"/>
                <measurement group_id="B5" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Vitreal VEGF Levels.</title>
        <time_frame>1 day (At the time of vitreous biopsy)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group 3 - Naive</title>
            <description>Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Anti-VEGF Plus AREDS-1 Supplementation.</title>
            <description>Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 - Anti-VEGF Plus AREDS-2</title>
            <description>Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Control</title>
            <description>Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Vitreal VEGF Levels.</title>
            <units>pg/ml</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="735.48"/>
                  <measurement group_id="O2" value="626.09"/>
                  <measurement group_id="O3" value="141.11"/>
                  <measurement group_id="O4" value="235.81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lipidomics Profile</title>
        <time_frame>1 day (At the time of vitreous biopsy)</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Foveal Thickness</title>
        <description>Measured with spectral-domain optical coherence tomography.</description>
        <time_frame>During at least 12 months of follow-up after vitreous biopsy.</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 3 - Naive</title>
          <description>Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.</description>
        </group>
        <group group_id="E2">
          <title>Group 2 - Anti-VEGF Plus AREDS-1 Supplementation.</title>
          <description>Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.</description>
        </group>
        <group group_id="E3">
          <title>Group 1 - Anti-VEGF Plus AREDS-2</title>
          <description>Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).</description>
        </group>
        <group group_id="E4">
          <title>Group 4 - Control</title>
          <description>Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Flavio Rezende</name_or_title>
      <organization>Maisonneuve-Rosemont Hospital</organization>
      <phone>514-867-2990</phone>
      <email>frezendef@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
